Get the Stockscreener App
19.23
6.69%
1.205
Viridian Therapeutics Inc stock is traded at $19.23, with a volume of 1.39M.
It is up +6.69% in the last 24 hours and up +13.35% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$18.02
Open:
$18.19
24h Volume:
1.39M
Relative Volume:
1.85
Market Cap:
$1.57B
Revenue:
$305.00K
Net Income/Loss:
$-328.98M
P/E Ratio:
-5.0196
EPS:
-3.83
Net Cash Flow:
$-309.60M
1W Performance:
+3.69%
1M Performance:
+13.35%
6M Performance:
+18.16%
1Y Performance:
+25.33%
1-Day Range:
$17.99
$19.60
1-Week Range:
$17.04
$19.60
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
19.23 | 1.48B | 305.00K | -328.98M | -309.60M | -3.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Trend Reversal Possible in Viridian Therapeutics Inc. Charts Indicate2025 Volume Leaders & Fast Gain Swing Alerts - beatles.ru
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront - MSN
Quant Strategy Flags Viridian Therapeutics Inc. for Entry2025 Investor Takeaways & Daily Oversold Bounce Ideas - classian.co.kr
Price Consolidation Hints at Upcoming Move in Viridian Therapeutics Inc.Weekly Market Summary & Weekly Setup with High ROI Potential - classian.co.kr
Identifying reversal signals in Viridian Therapeutics Inc.Earnings Summary Report & Free Safe Capital Growth Stock Tips - Newser
Statistical indicators supporting Viridian Therapeutics Inc.’s strength2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
Has Viridian Therapeutics Inc. found a price floorNew Guidance & Free Accurate Trade Setup Notifications - Newser
9 Best Small Cap Stocks with Biggest Upside Potential - Insider Monkey
Published on: 2025-08-17 06:00:45 - metal.it
How to forecast Viridian Therapeutics Inc. trends using time seriesPortfolio Value Summary & Weekly Market Pulse Updates - Newser
What momentum shifts mean for Viridian Therapeutics Inc.2025 Trading Volume Trends & Growth-Oriented Investment Plans - Newser
Applying Wyckoff theory to Viridian Therapeutics Inc. stockQuarterly Profit Summary & Verified Entry Point Signals - Newser
Published on: 2025-08-16 03:42:15 - 선데이타임즈
Published on: 2025-08-14 03:20:38 - beatles.ru
Will Viridian Therapeutics Inc. Bounce From 52 Week LowMarket Risk Report & Stepwise Trade Execution Plans - beatles.ru
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by XTX Topco Ltd - Defense World
RBC Capital Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $41 - 富途牛牛
Published on: 2025-08-14 00:53:45 - 선데이타임즈
Evercore ISI Maintains Buy Rating on Viridian Therapeutics with $38 Price Target - AInvest
Leerink Partnrs Issues Optimistic Outlook for VRDN Earnings - Defense World
Wedbush Research Analysts Boost Earnings Estimates for VRDN - Defense World
Lifesci Capital Has Negative Estimate for VRDN Q3 Earnings - Defense World
Royal Bank Of Canada Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $41.00 - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $30.00 - Defense World
Wells Fargo & Company Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $26.00 - Defense World
Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating - TipRanks
Viridian Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
Goldman Sachs Raises Price Target for Viridian Therapeutics (VRDN) to $30: Analysts' Forecasts and Ratings. - AInvest
Viridian Therapeutics Q2 Results Beat Expectations, Analysts Revise Forecasts - AInvest
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Benzinga
Oppenheimer Boosts Viridian Therapeutics' Target Price to $32.00, Maintaining 'Outperform' Rating. - AInvest
Wells Fargo Lowers Viridian Therapeutics Price Target to $26, Keeps Equal Weight Rating - AInvest
Viridian: Oppenheimer raises PT to $32 from $28, maintains Outperform rating. - AInvest
RBC Lowers Price Target on Viridian Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk - MarketScreener
Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo - TipRanks
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Viridian Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments - TipRanks
Viridian (VRDN) Reports Q2 Revenue Surpassing Estimates, Cash Position Supports Operations into 2027. - AInvest
Viridian Therapeutics Grants Inducement Stock Options to New Employees - AInvest
Viridian Therapeutics: Hold Rating and Awaited 2026 Developments - AInvest
Viridian 2025 Q2 Earnings Wider Losses Amid Regulatory and Partnership Momentum - AInvest
What data driven models say about Viridian Therapeutics Inc.’s futureCapital Secure Pattern Signal Analysis Sheet - Newser
Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating - TipRanks
Viridian (VRDN) Q2 Net Loss Widens 55% - AOL.com
Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments - TipRanks
Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements - TipRanks
Viridian Therapeutics Q2 Net Loss Widens, Revenue Increases - MarketScreener
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - BioSpace
Viridian Therapeutics Rises With Strong Cash And Clinical Progress - Finimize
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viridian Therapeutics Inc Stock (VRDN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Jun 09 '25 |
Option Exercise |
7.80 |
1,600 |
12,480 |
3,447,413 |
| Beetham Thomas W. | Chief Operating Officer |
Sep 27 '24 |
Buy |
23.41 |
5,000 |
117,050 |
6,000 |
| Mahoney Stephen F. | President and CEO |
Sep 27 '24 |
Buy |
23.33 |
21,400 |
499,262 |
21,400 |
| Fairmount Funds Management LLC | Director |
Sep 13 '24 |
Buy |
18.75 |
1,600,000 |
30,000,000 |
3,445,813 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):